摘要
目的:对比分析S-1单药和卡培他滨联合奥沙利铂两种化疗方案对Ⅱ期胃癌术后患者的有效性和安全性.方法:选取2017年12月~2020年2月在我院就诊的Ⅱ期胃癌术后患者200例,基于随机数字表法分为观察组(n=100)和对照组(n=100).观察组采用卡培他滨联合奥沙利铂治疗,治疗时间不少于4个周期,对照组采用S-1单药治疗,治疗时间不少于2个周期.术后随访,观察两组患者的有效性和安全性.结果:术后第一年两组的总生存情况与无瘤生存情况、术后第两年两组的总生存情况比较差异无统计学意义;与对照组比较,观察组近期疗效更优,术后第二年观察组的无瘤生存率、术后第三年的总生存率与无瘤生存率均更高,复发转移例数更少,病情改善人数更多,毒副作用发生率更高,且消化系统和血液系统方面的药物毒副作用发生率更高,差异均有统计学意义.两组患者CD3+、CD4+和CD4+/CD8+水平均显著高于治疗前,且观察组的升高幅度更多,差异均有统计学意义.结论:用于Ⅱ期胃癌术后患者时,奥沙利铂联合卡培他滨可显著提高患者生存率,增强机体免疫力,临床疗效优于S-1单药,但同时毒副反应发生率也更大,因此临床使用时应考虑患者的耐受性.
Objective To compare and analyze the efficacy and safety of S-1 single drug and capecitabine combined with oxaliplatin in postoperative patients with stageⅡgastric cancer.Methods 200 postoperative patients with stageⅡgastric cancer treated in our hospital from December 2017 to February 2020 were randomly divided into observation group(n=100)and control group(n=100).The observation group was treated with capecitabine combined with oxaliplatin,with a treatment cycle of no less than 4,and the control group was treated with S-l single drug,with a treatment cycle of no less than 2.The efficacy and safety of the two groups were observed.Results There was no significant difference in the overall survival between the two groups in the first year and the tumor free survival,and in the second year after operation;Compared with the control group,the short-term curative effect of the observation group is better,the tumor-free survival rate in the second year,the overall survival rate in the third year and the tumor-free survival rate of the observation group are higher,the number of recurrence and metastasis is less,the number of patients with disease improvement is more,the incidence of toxic and side effects is higher,and the incidence of drug toxic and side effects in digestive system and blood system is higher,The difference was statistically significant.The levels of CD3+,CD4+and CD4+/CD8+in the two groups were significantly higher than those before treatment,and the increase in the observation group was more significant.Conclusion When used in postoperative patients with stage II gastric cancer,oxalipla-tin combined with capecitabine can significantly improve the survival rate and enhance the body’s immunity.The clinical efficacy is better than S-l single drug,but the incidence of toxic and side effects is also greater.Therefore,the patient’s tolerance should be considered in clinical use.
作者
武四化
刘胜海
刘澎涛
李宏祥
周飞
Wu Si-hua;Liu Sheng-hai;Liu Peng-tao;Li Hong-xiang;Zhou Fei(Fuyang Tumor Hospitalof Anhui,Fuyang 236000,China)
出处
《湖南师范大学学报（医学版）》
2022年第2期180-183,共4页
Journal of Hunan Normal University(Medical Sciences)
关键词
奥沙利铂
卡培他滨
S-1
胃癌术后
oxaliplatin
capecitabine
S-l
postoperative gastric cancer
